Psoriasis

In this video, April W. Armstrong, MD, MPH, professor of dermatology and associate dean at Keck School of Medicine at USC, discusses how various psoriasis therapies should be positioned for personalizing patient care.

Although multiple therapies, including systemic and biologic treatments, are effective in treating psoriasis, topical agents are an important component of psoriasis management, according to April W. Armstrong, MD.

Long-term use of a combination halobetasol propionate and tazarotene lotion cleared psoriasis in patients with skin of color as well as white patients, according to a poster presentation at the Skin of Color Update virtual meeting.

COVID-19 mortality was not increased in patients on immunosuppressive biologics, according to a study.

Patients with psoriasis who received biologic drugs demonstrated a lower risk — that was statistically and clinically significant — for developing psoriatic arthritis, according to data published in Arthritis & Rheumatology.

The first patient has been enrolled in a phase 3 clinical trial of topical roflumilast foam for the treatment of scalp and body psoriasis, Arcutis Biotherapeutics announced in a press release.

Psoriasis is “mostly mild” in patients with psoriatic arthritis yet still impacts quality of life when measured using a dermatology-specific questionnaire, according to data published in Rheumatology.

In this issue of Healio Psoriatic Disease, we focus on shared dermatology-rheumatology clinics and how they aim to advance the treatment of psoriasis and psoriatic arthritis.

Psoriatic disease management needs input from both rheumatologists and dermatologists, and a growing number of practitioners have begun to combine clinics or collaborate efforts with their fellow specialists.

In this issue of Healio Psoriatic Disease, we focus on the advent of combined dermatology-rheumatology clinics for the management of patients with psoriatic disease.